QureBio Closes ￥10M Series A+ Round, To Accelerate the Pre-Clinical Development of Bispecific Antibody for Cancer

According to VCBeat, Shanghai-based Qure Biotechnology Co., Ltd. ("QureBio") announced today the completion of its Series A+ round of tens of millions yuan, with participation from Shenzhen Capital Group. Yixing Business Consulting served as the financial advisor.

Proceeds of this round will mainly be used to promote the pre-clinical development of QureBio's Q-1802 and Q-1801 projects. Previously, QureBio completed the angel round financing of nearly 10 million yuan, and the Series A round of tens of millions yuan respectively in May 2017 and August 2018. 

Founded in July 2017, QureBio is a research and development company focusing on the innovation of macromolecular drugs. The company aims to treat cancers, autoimmune diseases and metabolic diseases (such as diabetes, hyperlipidemia, etc.) and other difficult diseases, and actively develop biological therapy drugs.

QureBio has a number of independent platforms, covering the humanization platform of hybridoma antibody, phage display, single-domain antibody development, and antibody engineering. The company successfully completed several multiple transmembrane-spanning antigen projects by using its antibody humanization platform to solve the problem of immune tolerance. The synthesis library of human single-domain antibody and human antibody of the phage platform can be used to screen bispecific antibodies.

Relying on these platforms, QureBio is developing new biologics, and currently has nearly 10 pipelines under development, most of which are aimed at the challenging treatment of solid tumors. In particular, the company develops bispecific antibodies that modulate the tumor microenvironment in combination with T-cell immunotherapy. Both. It can not only remove the immunosuppression of tumor microenvironment, but also precisely kill cancer cells.

SCGC is a limited venture capital company established by Shenzhen Government in 1999. SCGC has a registered capital of 5.42 billion yuan. It primarily invests in SMEs, innovative high-tech enterprises, enterprises in emerging industries, and enterprises in the start-up period, growth period and in transformation, covering industries supported by national policies, including IT, internet, new media, biopharma, new energy, environmental protection, chemical engineering, new material, high-end equipment manufacturing, consumer goods, modern service, etc.